NCT07131670 Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes
| NCT ID | NCT07131670 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qian Chu |
| Condition | Lung Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2024-06-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This prospective observational study aims to evaluate symptom burden and symptom clusters among lung cancer patients undergoing definitive concurrent chemoradiotherapy (CRT), based on electronic patient-reported outcomes (ePROs). Patients will complete the validated MDASI-LC and EQ-5D instruments weekly from baseline through the end of CRT and for 12 weeks post-treatment. The study will characterize the longitudinal trajectories of symptom severity and interference, identify distinct symptom clusters and their temporal patterns, and explore patient-level predictors of symptom burden. The findings may support the development of personalized symptom management strategies and improve quality of life during and after CRT.
Eligibility Criteria
Inclusion Criteria: * Pathologically confirmed unresectable stage III NSCLC or limited-stage SCLC * Age ≥ 18 years * Receiving definitive chemoradiotherapy * Able and willing to complete electronic questionnaires * Provided written informed consent Exclusion Criteria: * Severe comorbidities (heart, liver, kidney) * Psychiatric illness or cognitive impairment * Prior chest or mediastinal radiotherapy
Frequently Asked Questions
Who can join the NCT07131670 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07131670 currently recruiting?
Yes, NCT07131670 is actively recruiting participants. Visit ClinicalTrials.gov or contact Qian Chu to inquire about joining.
Where is the NCT07131670 trial being conducted?
This trial is being conducted at Wuhan, China.
Who is sponsoring the NCT07131670 clinical trial?
NCT07131670 is sponsored by Qian Chu. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.